| 000 | 01731 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516190543.0 | ||
| 264 | 0 | _c20140710 | |
| 008 | 201407s 0 0 eng d | ||
| 022 | _a1097-0142 | ||
| 024 | 7 |
_a10.1002/cncr.28518 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBadrising, Sushil | |
| 245 | 0 | 0 |
_aClinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. _h[electronic resource] |
| 260 |
_bCancer _cApr 2014 |
||
| 300 |
_a968-75 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Multicenter Study; Observational Study | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAndrostenes |
| 650 | 0 | 4 |
_aAndrostenols _xtherapeutic use |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 | _aBenzamides |
| 650 | 0 | 4 | _aDocetaxel |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNitriles |
| 650 | 0 | 4 |
_aPhenylthiohydantoin _xadverse effects |
| 650 | 0 | 4 |
_aProstatic Neoplasms, Castration-Resistant _xdrug therapy |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aTaxoids _xtherapeutic use |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _avan der Noort, Vincent | |
| 700 | 1 | _avan Oort, Inge M | |
| 700 | 1 | _avan den Berg, H Pieter | |
| 700 | 1 | _aLos, Maartje | |
| 700 | 1 | _aHamberg, Paul | |
| 700 | 1 | _aCoenen, Jules L | |
| 700 | 1 | _avan den Eertwegh, Alfons J M | |
| 700 | 1 | _ade Jong, Igle J | |
| 700 | 1 | _aKerver, Emile D | |
| 700 | 1 | _avan Tinteren, Harm | |
| 700 | 1 | _aBergman, Andries M | |
| 773 | 0 |
_tCancer _gvol. 120 _gno. 7 _gp. 968-75 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/cncr.28518 _zAvailable from publisher's website |
| 999 |
_c23409729 _d23409729 |
||